Nektar Therapeutics (NKTR) stock
NKTR's Quality Score fell 1 point on Tue, Oct 6, to -10. Its range widened again.
Follow NKTR's trial news. Pro members can get an alert when Nektar Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
Sales down 40%, $92.1M → $55.2M in 3 years.
4 more reasons behind NKTR's -10, for Pro members
What's next for NKTR, and how long its cash lasts
From Nektar Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 11 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Nov 12, 2025)
- At-the-market share sales program (424B5, filed May 8, 2026)
Insiders
Chief R&D Officer Jonathan Zalevsky sold 186 shares on Aug 18. 9 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why NKTR is down
Nektar Therapeutics fell 22.4% on Oct 1; it filed an 8-K (items 7.01, 9.01) that day.
The SEC accepted its 8-K (items 7.01, 9.01) on Oct 1 at 7:57 AM ET, before the open.
−2Long-term trend below a falling 200-day average, down over one year
1 more driver, the timeline, and the peer table, for Pro members
5 more things pulling NKTR's score down, for Pro members
What's next
Expected to report Thu Nov 12, after the close
After its last 4 reports it closed 0.0% on average, higher 2 of 4 times.
What would turn NKTR's score around: 9 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Nothing is firing on NKTR right now
One per group is shown here.
Also on the chart
- RSI 1419.8
- MACD (12, 26, 9)Below signal
- 50-day average$68.28
- 200-day average$65.35
- ADX 1432.8
- Support$34.34
- Resistance$45.34
- Volume1.0x
How NKTR ranks in Biotech
NKTR is #299 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
NAMSOpen for its score
NBIXOpen for its score
NRIXOpen for its score
NKTR0/14-10
When does NKTR report earnings, and what happens after?
Expected to report Thu Nov 12, after the close (in 37 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 13, 2026After close | After close | -2.5% | -3.8% | -1.8% |
| May 7, 2026After close | After close | +1.9% | -1.8% | -10.8% |
| Mar 12, 2026After close | After close | +3.2% | +4.1% | +6.4% |
| Nov 6, 2025After close | After close | +1.6% | +1.5% | -2.1% |
Who is trading NKTR
NKTR insider trades
2 insiders sold $43K across 2 filings in the last 6 months. No open-market buys on record. The newest:
NKTR's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of NKTR's score, with the points and the reason
- All 14 checks on NKTR and on all 3,244 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on NKTR
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.